まとめ
エルゴタミンタルトラートは,血圧を上昇させ,症状を改善することによって,慢性正規性低血圧を効果的に治療します. この血管圧縮薬は最小限の毒性を示し,患者における血小板α受容体を正常化させることができる.
科学分野:
- 薬理学 薬理学とは
- 心血管医学 心血管医学
- ネフロロジーはネフロロジーを用います.
背景:
- 慢性正静性低血圧 (COH) は,立ち上がったときに血圧が著しく低下することを特徴とする衰弱状態です.
- COHの現在の治療法は限られており,しばしば重大な副作用が伴う.
- COHにおけるアルファアドレネルゲン受容体とその調節の役割については,さらなる調査が必要である.
研究 の 目的:
- COHの患者におけるエルゴタミンタルトレートの急性および慢性効果および安全性を評価する.
- エルゴタミンの血圧上昇効果の根底にある血液動力学的メカニズムを調査するために.
- 血小板α受容体,ノルエピネフリン濃度,およびエルゴタミンの治療反応の関係を探求する.
主な方法:
- COHの患者4人は,慢性的な経口エルゴタミンタルトレートを受けた.
- 急性血液動力学的評価には,静脈注射エルゴタミンタルトレートによる横横と直立の傾きに関する研究が含まれていた.
- 前腕のプレチスモグラフィーと血小板α受容体の密度測定を行いました.
主要な成果:
- 慢性的な経口エルゴタミンタルトラートは,横たわる高血圧を引き起こすことなく,立った状態で血圧を大幅に上昇させ,臨床症状を改善しました.
- 静脈内投与エルゴタミンタルトレートは,全周回路抵抗と垂直傾斜時の心臓出力を増加させ,全身血管収縮を示した.
- 患者は血小板α受容体の増加を示し,慢性的なエルゴタミン療法で正常化しました.
結論:
- エルゴタミンタルトラートは,慢性正規性低血圧の選択患者にとって貴重な治療法です.
- エルゴタミンの血圧上昇効果は,動脈と静脈の両方の血管収縮に起因する.
- エルゴタミンの治療は,COHの患者におけるアルファ-アドレナジック受容体の機能を調節する可能性があります.
関連する概念動画
01:30Adrenergic Agonists: Therapeutic Uses
Adrenergic agonists have diverse therapeutic uses across various medical conditions and emergencies.
Emergency and Intensive Care Unit (ICU) applications: Pressor agents increase blood pressure, heart rate, and contractility in shock and organ failure situations. Dopamine can induce vasodilation and stimulate adrenoceptors. Endogenous catecholamines are effective in treating cardiogenic shock. α2-agonists like clonidine can reverse anesthesia-induced hypertension.
Allergies and anaphylaxis:...
Emergency and Intensive Care Unit (ICU) applications: Pressor agents increase blood pressure, heart rate, and contractility in shock and organ failure situations. Dopamine can induce vasodilation and stimulate adrenoceptors. Endogenous catecholamines are effective in treating cardiogenic shock. α2-agonists like clonidine can reverse anesthesia-induced hypertension.
Allergies and anaphylaxis:...
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
01:24Parkinson's Disease: Treatment
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of its...
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of its...
01:28Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors
Phosphodiesterase 5 (PDE5) inhibitors are potent enzymes that function to hydrolyze cyclic nucleotides to their corresponding 5' monophosphates. Their unique biochemical properties have been applied in treating Pulmonary Arterial Hypertension (PAH).
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
01:30Heart Failure V: Medical Management
Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
01:28Hypertension IV: Drug Therapy and Lifestyle Modifications
Multiple classes of antihypertensive medications are employed in treating hypertension. The most commonly recommended first-line treatments include:Thiazide Diuretics, such as chlorthalidone, increase sodium and water excretion from the body, reducing blood volume and blood pressure.Angiotensin-converting enzyme inhibitors, like lisinopril, block the conversion of angiotensin I to II, a potent vasoconstrictor lowering blood pressure.Angiotensin II Receptor Blockers (ARBs) prevent angiotensin II...